Screening in the UK - call for a national authority to rationalise procedures
This article was originally published in Clinica
Screening policy in the UK is fragmented, implemented ineffectively and at times a waste of resources, according to a UK healthcare expert. Despite the availability of effective screening tools for a number of diseases, programmes are inefficient because they are run by district health authorities rather than a single national authority, said Malcolm Law of the Wolfson Institute of Preventive Medicine at St Bartholomew's Hospital, London.
You may also be interested in...
AMAG outlines plans for retrospective real-world evidence studies, and possibly a new placebo-controlled trial with a primary endpoint of preterm birth <32 weeks, in a filing opposing the Center for Drug Evaluation and Research’s proposal to withdraw the drug.
The leading Korean pharma firm’s oral, third-generation EGFR-TKI is approved in the country, providing a new option for patients with advanced NSCLC and increasing hopes for global approvals given an ongoing global Phase III combination trial led by partner J&J.
DePuy Synthes expects its Velys robotic-assisted system to be cost-effective, easy-to-use and to be well-suited for use in ambulatory surgery centers.